natgillin/translations-raw huggingface dataset:
The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form.
Pri enkratnem odmerjanju je bila interindividualna variabilnost farmakokinetičnih parametrov rivastigmina (normalizirana na odmerek/kg telesne mase) 43% za Cmax in 49% za AUC0-24h pri transdermalni aplikaciji v primerjavi s 74% za Cmax in 103% za AUC0-24h pri uporabi peroralne oblike.
The single-tablet regimen (STR), Eviplera, has been studied in virologically suppressed patients who switched from a regimen containing a ritonavir-boosted protease inhibitor (Phase III study GS-US-264-0106) or from efavirenz/emtricitabine/tenofovir disoproxil fumarate (Phase IIb study GS-US-264-0111).
Zdravilo Eviplera so z režimom odmerjanja z eno samo tableto preučili pri bolnikih z virološko supresijo, ki so prešli z režima, ki je vseboval zaviralec proteaze, okrepljen z ritonavirjem (študija faze III GS-US-264-0106), ali z efavirenza/emtricitabina/dizoproksiltenofovirijevega fumarata (študija IIb. faze GS-US-264-0111).
the site and intensity of the bleeding
mesta in obsega krvavitve,
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.
Za vsako naslednje injiciranje je treba izbrati drugo mesto na telesu, da se preprečijo spremembe na koži (kot je odebelitev), zaradi česar ima lahko insulin slabši učinek od pričakovanega.
The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the medicine work less well than expected.
Za vsako injiciranje je treba izbrati drugo mesto na telesu, da se preprečijo spremembe na koži (na primer odebelitev), zaradi česar je lahko zdravilo manj učinkovito od pričakovanega.
The site of injection should be changed with each injection.
Mesto injiciranja je treba pri vsakem injiciranju menjati.
The site of injection should be changed.
Mesto injiciranja je treba menjati.
The site of injection should be varied each week.
Mesto injiciranja je treba vsak teden zamenjati.
The site of the procedure should be observed for signs of bleeding or haematoma formation.
Mesto posega je treba nadzirati, da bi odkrili znake krvavitve ali nastanka hematoma.
The site of the sodium chloride 9 mg/ml (0.9%) solution for injection bag where the needle is going to be inserted should be swabbed with an alcohol pad.
Mesto, kjer boste vrečko z raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje prebodli z iglo, morate obrisati z alkoholno blazinico.
The size of the capsule is ‘Size 1’ (dimensions 19.0 x 6.6 mm).
Velikost kapsule je "Velikost 1" (dimenzije 19,0 x 6,6 mm).
The size of the capsule is ‘size 1’ (dimensions 19.4 x 6.9 mm).
Velikost kapsule je „velikost 1“ (mere 19,4 x 6,9 mm).
The size of the fibroids was also smaller in women treated with Esmya than in those who received the placebo.
Prav tako je bila velikost leiomiomov manjša pri ženskah, ki so se zdravile z zdravilom Esmya, kot pri tistih, ki so prejemale placebo.
The size of the syringe (1 ml, 3 ml or 5 ml) will be included in your prescription.
Velikost brizge (1 ml, 3 ml ali 5 ml) bo navedena na receptu.
the size of your body (measured in ‘square meters’ or ‘m2’)
vaše telesne površine (izražena v kvadratnih metrih oz. ‘m2’);
The skeletal effects of parathyroid hormone depend upon the pattern of systemic exposure.
Učinki obščitničnega hormona na okostje so odvisni od vzorca sistemske izpostavljenosti.
The skin discolouration generally disappears over a few days to weeks as the drug is cleared.
Sprememba barve kože na splošno izgine po nekaj dnevih do nekaj tednih po izločitvi zdravila iz telesa.
The skin feels very hot with little or no sweating, or the child becomes confused or has muscle cramps, or the child’s heartbeat or breathing become rapid.
Koža postane na otip koža zelo vroča in znojenja je zelo malo ali ga ni, ali otrok postane zmeden ali ima mišične krče ali postaneta srčni utrip ali dihanje hitrejša:
The skin fold can be released after needle insertion.
Po vstavitvi igle kožno gubo izpustite.
the skin of your face is irritated or has open wounds.
je vaša koža na obrazu razdražena ali ima odprte rane.
The skin rash commonly resembles acne and often involves the face, upper chest and back, but can affect any area of the body.
Kožni izpuščaj je pogosto podoben aknam in pogosto vključuje obraz, zgornji del prsnega koša in hrbta, vendar lahko prizadene kateri koli predel na telesu.
the skin, check
kože, za
The SLE Responder Index measures improvement in SLE disease activity, without worsening in any organ system, or in the patient’s overall condition.
Indeks odziva SLE meri izboljšanje aktivnosti SLE brez poslabšanja v kateremkoli organskem sistemu ali bolnikovem splošnem stanju.
The slope is higher in patients with clinically significant hepatic impairment.
Naklon je večji pri bolnikih s klinično pomembno jetrno okvaro.
The slow blinking green light means IONSYS is ready to dose.
Počasi utripajoča zelena lučka pomeni, da je sistem IONSYS pripravljen na odmerjanje.
The slower you press, the easier the injection will feel.
Počasneje ko boste pritiskali, lažji bo občutek pri injiciranju.
The small air bubbles will not harm you.
Majhni mehurčki zraka vam ne bodo škodovali.
The small amount of drug which was absorbed into the systemic circulation was promptly excreted by both urinary and faecal routes at a mean ratio of approximately 3 to 1.
Majhna količina zdravila, ki se je absorbirala v sistemski obtok, je bila hitro izločena tako z urinom kot blatom s povprečnim razmerjem približno 3 proti 1.
the small green spoon measures 100 mg of betaine anhydrous powder;
z malo žličko odmerite 100 mg betaina v obliki brezvodnega praška;
The small increase in β agonist-related adverse events should be taken into account if doubling the dose of salmeterol/fluticasone propionate is considered by the physician in adult patients requiring additional short- term (up to 14 days) inhaled corticosteroid therapy.
Če zdravnik razmišlja, da bi odmerek salmeterola/flutikazonpropionata pri odraslih bolnikih, ki potrebujejo dodatno kratkoročno (do 14-dnevno) zdravljenje z inhalacijskimi kortikosteroidi, podvojil, mora upoštevati majhno povečanje neželenih učinkov, povezanih z agonisti β.
The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy.
Nekoliko zmanjšana AUC predvidoma ne zmanjša terapevtične učinkovitosti.
The SmPC for concomitantly used products must be consulted for the recommendations regarding co-administration with strong CYP3A4 inhibitors.
Za priporočila glede sočasnega dajanja z močnimi zaviralci CYP3A4 je treba preveriti povzetke glavnih značilnosti sočasnih zdravil.
The SmPC of the actual SSRI/SNRI should be consulted on how to withdraw the treatment to avoid this.
Da bi preprečili njihov pojav, morate o tem, kako prekiniti zdravljenje, natančno prebrati povzetek glavnih značilnosti antidepresiva iz skupine SSRI/SNRI, s katerim se bolnik zdravi.
The SmPC section 4.4 includes a warning/precaution of use in children treated with high doses of Cystagon based on already reported cases of EDS on elbows, recommending to monitor regularly skin and to consider X-ray examination of the bone, and to decrease the dose of Cystagon if any similar or bone abnormality appear.
Poglavje 4.4 SmPC-ja vsebuje opozorilo/svarilo glede uporabe pri otrocih, ki se zdravijo z velikimi dozami cystagona, ki temelji na poročilih o primerih EDS-a na komolcih, priporočilo glede rednega opazovanja kože in napotek za rentgenski pregled kosti ter zmanjšanje doze cystagona, če bi se pojavila kakšna podobna anomalija ali nepravilnosti na kosti.
The sodium chloride 9 mg/ml (0.9%) solution for injection is added to the vial by slow, firm depression of the syringe plunger.
Raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje dodajte v vialo, tako da počasi in trdno pritiskate bat brizge.
The solid pieces contain the medicine – do not chew or crush them.
Trdni delci vsebujejo zdravilo – ne žvečite jih in jih ne drobite.
The solubility of lapatinib is pH-dependent.
Topnost lapatiniba je odvisna od pH.
The solution (stabiliser) contains citric acid monohydrate (E330), lysine hydrochloride, polysorbate 80, sodium hydroxide and water for injections.
Raztopina (stabilizator) vsebuje citronsko kislino monohidrat (E330), lizinijev klorid, polisorbat 80, natrijev hidroksid in vodo za injekcije.
The solution also contains potassium sorbate and sorbitol (E420).
Raztopina vsebuje tudi kalijev sorbat in sorbitol (E 420).
The solution also contains potassium sorbate and sorbitol (E420).
Raztopina vsebuje tudi kalijev sorbat in sorbitol (E420).
The solution can be diluted with 5 % glucose solution or sodium chloride 9 mg/ml (0.9%) solution for injection before intravenous injection.
Raztopino lahko pred intravenskim injiciranjem razredčite s 5 % raztopino glukoze ali 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
The solution can be taken with or without food.
Raztopino lahko jemljete s hrano ali brez.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Raztopino, ki vsebuje zoledronsko kislino, dajemo v obliki ene same 15-minutne intravenske infuzije z ločenim infuzijskim sistemom.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Raztopino, ki vsebuje zoledronsko kislino, je treba dati kot samostojno 15-minutno intravensko infuzijo z ločenim infuzijskim sistemom.
The solution containing Zoledronic acid medac is given as a single 15-minute intravenous infusion.
Raztopino, ki vsebuje zdravilo Zoledronska kislina medac, dajemo v obliki ene same 15- minutne intravenske infuzije z ločenim infuzijskim sistemom.
The solution containing zoledronic acid must not be further diluted or mixed with other infusion solutions.
Raztopine, ki vsebuje zoledronsko kislino, ne smete nadalje redčiti ali mešati z drugimi infuzijskimi raztopinami.
The solution for infusion is an alternative form of treatment for a short period of time, when Vimpat can't be taken by mouth.
Raztopina za infundiranje je alternativna oblika kratkotrajnega zdravljenja, kadar zdravila Vimpat ne morete jemati skozi usta.
The solution for infusion is infused over a period of 15 to 60 minutes twice daily.
Raztopino za infundiranje infundiramo dvakrat dnevno 15 do 60 minut.
The solution for infusion is sterile, translucent and red.
Raztopino za infundiranje je sterilna, prosojna in rdeče barve.
The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25°C. Do not freeze.
24 urah je raztopina lahko največ 4 ure shranjena pri temperaturi do 25°C. Ne zamrzujte.
The solution for infusion may be stored for a maximum of 4 hours of the total 24 hours below 25°C. Infusion must be completed within 24 hours of reconstitution of the powder.
V teh 24 urah je raztopina lahko največ 4 ure shranjena pri temperaturi do 25°C. Infundiranje morate dokončati v 24 urah po raztapljanju praška.
The solution for infusion should be infused intravenously over 20 – 50-minutes.
Raztopino za infundiranje je treba infundirati intravensko v 20-50 minutah.
The solution for infusion should be infused intravenously over 20 – 50-minutes.
Raztopino za infundiranje je treba infundirati intravensko v 20–50 minutah.
The solution for injection can be stored between 2C to 30C for no more than 8 hours.
Raztopina za injiciranje je lahko shranjena pri temperaturi od 2 C do 30 C največ 8 ur.
The solution for injection caused a gradual decrease in pain scores in cats and dogs after the operation.
Raztopina za injiciranje je povzročila postopno zmanjšanje bolečine pri mačkah in psih po operativnem posegu.
The solution for injection is given as an injection under the skin to cats or dogs around 30 minutes before the start of the operation at a dose of 2 mg/kg.
Raztopina za injiciranje se mačkam ali psom injicira v podkožje približno 30 minut pred začetkom operativnega posega, pri čemer je odmerek 2 mg/kg.
The solution for injection is only for use in rheumatoid arthritis and is given as an injection under the skin once a week.
Raztopina za injiciranje se uporablja samo pri revmatoidnem artritisu in se daje kot injekcija v podkožje enkrat tedensko.
The solution for injection is used for the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery, such as neutering.
Raztopina za injiciranje se uporablja za zdravljenje bolečin in vnetij po operativnih posegih na kosteh ali mehkih tkivih, kot je sterilizacija.
The solution for injection is used for the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery.
Raztopina za injiciranje se uporablja za zdravljenje bolečin in vnetij po operativnih posegih na kosteh ali mehkih tkivih.
The solution for injection or infusion comes as a clear, colourless, aqueous solution.
Raztopina za injiciranje ali infundiranje je bistra, brezbarvna, vodna raztopina.
The solution for injection should be administered subcutaneously each day.
Raztopino za injiciranje je treba aplicirati subkutano vsak dan.
The solution for injection was compared with placebo over a period of two hours in two studies involving 805 adults with schizophrenia or related conditions who were experiencing symptoms of agitation.
V dveh študijah, v katerih je sodelovalo 805 odraslih s shizofrenijo ali sorodnimi stanji, ki so imeli simptome agitacije, so raztopino za injiciranje v obdobju dveh ur primerjali s placebom.
The solution for injection was studied in cats and dogs undergoing surgery.
Raztopina za injiciranje je bila raziskana na mačkah in psih, pri katerih je bil opravljen operativni poseg.
the solution in the pre-filled syringe is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
da je raztopina v napolnjeni injekcijski brizgi bistra do rahlo opalescentna (ima biserni sijaj) in brezbarvna do rumenkasta,
the solution in the pre-filled syringe is not discoloured or cloudy and does not contain any foreign particles the solution in the pre-filled syringe is not frozen.
da raztopina v napolnjeni injekcijski brizgi ni spremenila barve ali je motna, da ne vsebuje tujih delcev in da raztopina v napolnjeni injekcijski brizgi ni zmrznjena.
the solution in the vial is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow
da je raztopina v viali bistra do rahlo opalescentna (ima biserni sijaj) in brezbarvna do rumenkasta,
The solution in the vials should not be used if it is discoloured or if particulate matter is present.
Ne uporabljajte, če je raztopina v vialah spremenila barvo ali če so v njej prisotni delci.
The solution is a clear, colourless to pale yellow and iso-osmotic solution.
Raztopina je bistra, brezbarvna do bledorumena in izoosmotska.
The solution is a practically clear, orange solution for oral administration.
Raztopina je skoraj bistra, oranžna raztopina za peroralno uporabo.
The solution is administered subcutaneously at a dose of 3 x 250 IU/kg b.w. per week.
Raztopino dajemo subkutano v odmerku 3 x 250 i.e./kg telesne mase na teden.
the solution is any other colour than colourless to slightly yellow the pen has been dropped or is visibly damaged.
raztopina ni brezbarvna do rumenkasta, temveč drugačne barve. je injekcijski peresnik padel na tla ali je vidno poškodovan.
the solution is clear and colourless and doesn’t contain particles the syringe has not been opened or damaged
če je raztopina bistra in brezbarvna ter ne vsebuje delcev. da injekcijska brizga še ni bila odprta ali poškodovana.
the solution is clear and colourless and doesn’t contain particles the syringe has not been opened or damaged
če je raztopina bistra in brezbarvna ter ne vsebuje delcev; da injekcijska brizga še ni bila odprta ali poškodovana.
The solution is clear and colourless to light yellow.
Raztopina je bistra in brezbarvna do rahlo rumene barve.
the solution is clear and colourless to slightly yellow and doesn’t contain particles the syringe has not been opened or damaged
če je raztopina bistra in brezbarvna ter ne vsebuje delcev. da injekcijska brizga še ni bila odprta ali poškodovana.
the solution is clear and colourless to slightly yellow and doesn’t contain particles the syringe has not been opened or damaged
če je raztopina bistra in brezbarvna ter ne vsebuje delcev; da injekcijska brizga še ni bila odprta ali poškodovana.
The solution is clear and colourless to slightly yellowish.
Raztopina je bistra in brezbarvna do rahlo rumenkasta.
The solution is clear and pale yellow or light brown.
Raztopina je bistra in bledorumena ali svetlorjava.
The solution is clear and pale-yellow or light-brown.
Raztopina je prozorna in je bledo rumene ali svetlo rjave barve.
The solution is clear or slightly opalescent and colourless or pale yellow.
Raztopina je bistra ali rahlo opalescentna in brezbarvna ali bledorumena.
The solution is clear or slightly opalescent and colourless or pale-yellow.
Raztopina je bistra ali rahlo opalescentna in brezbarvna ali bledo rumena.
The solution is clear or slightly opalescent and colourless to pale-yellow.
Raztopina je bistra do rahlo opalescentna, brezbarvna do bledo rumena.
The solution is clear to slightly opalescent (having a pearl-like shine), colourless to light yellow and may contain a few small translucent or white particles of protein.
Raztopina je bistra do rahlo opalescentna (tj. ima biserni sij) ter brezbarvna do rahlo rumenkasta in lahko vsebuje nekaj majhnih prosojnih ali belih delcev beljakovin.
The solution is clear to slightly opalescent, colourless to light yellow.
Raztopina je bistra do rahlo opalescentna in brezbarvna do rahlo rumenkasta.
The solution is clear, and colourless or pale yellow.
Raztopina je bistra in brezbarvna ali bledorumena.
The solution is clear, colorless to pale yellow with a pH of 6.8 to 7.4.
Bistra, brezbarvna do bledo rumena raztopina z vrednostjo pH od 6,8 do 7,4.
The solution is clear, colourless to light yellow.
Raztopina je bistra do rahlo opalescentna in brezbarvna do svetlo rumena.
The solution is clear, colourless to pale yellow and aqueous.
Raztopina je bistra, brezbarvna do bledo rumena vodna raztopina.
the solution is cloudy or you can see particles floating in it
je raztopina motna ali v njej opazite plavajoče delce.
The solution is coloured or you can see particles floating in it.
da je raztopina obarvana ali v njej opazite delce, da je varnostna zaporka zlomljena.
The solution is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and plunger heads and are secured with aluminium seals.
Raztopina je pakirana v steklene vložke iz kremenovega stekla tipa I, zaprte s tesnilno ploščico iz butilne ali halobutilne gume in z batnim zamaškom ter zaščitene z aluminijasto zaporko.
The solution is light yellow to golden.
Raztopina je svetlo zelene do zlate barve.
The solution is NOT clear, colourless and free of particles
Raztopina NI bistra, brezbarvna in brez delcev
the solution is not discoloured or cloudy and does not contain any foreign particles the solution is not frozen.
da raztopina ni spremenila barve ali je motna, da ne vsebuje tujih delcev in da ni zamrznjena.
The solution is to be discarded if visible particulate matter or discolouration is observed.
Če opazite v raztopini drobne delce ali spremembo barve, jo morate zavreči.
The solution is to be discarded if visible particulate matter or discolouration is observed.
Če raztopina vsebuje drobne delce ali je obarvana, jo morate zavreči.
The solution is to be mixed gently for infusion.
Raztopino je treba pred pričetkom infuzije rahlo pretresti.
The solution is to be visually inspected for particulate matter prior to use.
Pred redčenjem se je treba prepričati, da raztopina ne vsebuje vidnih delcev.
The solution is water clear, colourless and aqueous.
Raztopina je povsem bistra, brezbarvna in vodna.
The solution made up by a pharmacist is preferable to a home preparation as a pharmacist can measure the dose more accurately.
Suspenzija, ki jo pripravi farmacevt, je bolj priporočljiva od doma pripravljenega pripravka, saj lahko farmacevt odmerek natančneje odmeri.
The solution may develop a few fine translucent particles, as infliximab is a protein.
V raztopini se lahko pojavi nekaj finih prosojnih delcev, saj je infliksimab beljakovina.
The solution may only be dispensed in the unlocked position.
Raztopino lahko oddeljujemo samo v odlkenjenem položaju.
The solution must be allowed to reach room temperature before administration.
Pred dajanjem mora raztopina doseči sobno temperaturo.
The solution must be brought to room temperature before use.
Raztopina naj se pred injiciranjem ogreje na sobno temperaturo.
The solution must be diluted further before it can be infused.
Raztopino je treba pred pričetkom infuzije rahlo pretresti.
The solution must therefore be handled and administered with particular care.
Z raztopino morate ravnati in jo dajati s posebno previdnostjo.
The solution of reconstituted Xigris must be further diluted with sterile 0.9% Sodium Chloride Injection to a final concentration of between 100 g/ml and 200 g/ml.
Raztopino rekonstituiranega zdravila Xigris morate nadalje razredčiti s sterilno 0,9 % raztopino natrijevega klorida do končne koncentracije, ki je med 100 g/ml in 200 g/ml.
The solution should be a clear to slightly turbid, colourless to light-yellow to yellow solution, essentially free from visual particulates.
Raztopina mora biti bistra do rahlo motna, brezbarvna do svetlo rumena do rumena, praktično brez vidnih delcev.
The solution should be administered immediately after opening the syringe.
Raztopino je treba aplicirati takoj po odprtju injekcijske brizge.
The solution should be administered immediately after opening the syringe.
Raztopino uporabite takoj po odprtju injekcijske brizge.
The solution should be administered orally three hours (range 2-4 hours) before anaesthesia.
Raztopino je treba dati peroralno tri ure (interval 2–4 ur) pred anestezijo.
The solution should be administered slowly, at a rate as determined by the patient’s comfort level, not to exceed 10 ml per minute.
Raztopino je treba dajati počasi, s hitrostjo, ki zagotavlja ugodje bolnika, in sicer največ 10 ml na minuto.
The solution should be administered slowly, at a rate as determined by the patient’s comfort level, not to exceed 10 ml per minute. (See Section 4 “Possible side effects”).
Injicirajte jo počasi, s hitrostjo, ki naj bo odvisna od bolnikovega počutja, vendar ne sme preseči 10 ml na minuto (glejte poglavje 4 ”Možni neželeni učinki”).
The solution should be administered within one hour after removal from the 2°C to 8°C storage.
Raztopino je treba aplicirati v roku 1 ure po premestitvi iz okolja s temperaturo med 2 °C in 8 °C.
The solution should be allowed to reach a comfortable temperature (15 °C - 25 °C) for injection.
Raztopina mora pred injiciranjem doseči prijetno temperaturo (15 °C – 25 °C).
The solution should be clear after removal from the refrigerator.
Po hranjenju raztopine v hladilniku mora biti ta bistra.
The solution should be clear and colourless and free from visible particles.
Raztopina mora biti bistra in brezbarvna ter brez vidnih delcev.
The solution should be clear and colourless to pale yellow, with no lumps, flakes or particles.
Raztopina mora biti bistra in brezbarvna ali bledo rumene barve in ne sme vsebovati kepic, kosmičev ali delcev.
The solution should be clear and colourless, with no lumps, flakes, or particles.
Raztopina mora biti bistra in brezbarvna ter ne sme vsebovati kepic, kosmičev ali delcev.
The solution should be clear and pale-yellow or light-brown.
Raztopina je bistra in bledo rumene ali svetlo rjave barve.
The solution should be clear immediately after removal from the refrigerator.
Raztopina mora biti bistra takoj, ko jo vzamete iz hladilnika.
The solution should be clear immediately after removal from the refrigerator.
Takoj, ko vzamete raztopino iz hladilnika, mora biti bistra.